Overview

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

This study is a prospective, open-label, single-arm phase II clinical study to evaluate the safety and efficacy of zanubrutinib plus R-CHOP (ZR-CHOP) as the first-line therapy for newly diagnosed diffuse large B-cell lymphoma patients with high-risk factors.

Phase:

Phase 2

Details

Lead Sponsor:

Liaoning Tumor Hospital & Institute

Treatments:

Cyclophosphamide
Epirubicin
Prednisone
Rituximab
Vincristine
Zanubrutinib